|Mr. Ming Hsieh||Chairman, CEO & Pres||248k||N/A||1956|
|Mr. Paul Kim||Chief Financial Officer||253.66k||N/A||1967|
|Mr. Jian Xie||Chief Operating Officer||224.54k||N/A||1966|
|Dr. Han Lin Gao FACMG, M.D., Ph.D., D.A.B.M.G., F.A.C.M.G.||Chief Scientific Officer & Laboratory Director||223.51k||N/A||1967|
|Mr. Brandon Perthuis||Chief Commercial Officer||N/A||N/A||N/A|
|Dr. Lawrence M. Weiss M.D.||Chief Medical Officer||N/A||N/A||1957|
Fulgent Genetics, Inc., together with its subsidiaries, provides COVID-19 testing and genetic testing services to physicians with clinically actionable diagnostic information. Its technology platform integrates data comparison and suppression algorithms, adaptive learning software, and genetic diagnostics tools and integrated laboratory processes. The company primarily serves insurance, hospitals, and medical institutions. It sells its tests through internal sales force, as well as through independent sales representatives in the United States and internationally. Fulgent Genetics has collaboration with PWNHealth to provide at-home COVID-19 test capabilities; and has strategic partnership with Helio Health, Inc. to commercialize blood-based early cancer detection tests. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. Fulgent Genetics, Inc. was founded in 2011 and is headquartered in Temple City, California.
Fulgent Genetics, Inc.’s ISS governance QualityScore as of 26 September 2021 is 7. The pillar scores are Audit: 5; Board: 7; Shareholder rights: 4; Compensation: 9.